Providing patients with access to research as a healthcare option is important to better outcomes of clinical research.
FREMONT, CA: Leading healthcare-enabling research organization Elligo Health Research announces the launch of its fully realized System of Accelerated Research (SOAR) model for decentralized (DCTs) and hybrid trial models with fully remote monitoring capabilities. This tech-enabled solution is created to keep the patient and physician at the heart of its design while offering transparency to providers. The company’s goal is to provide all patients with access to research as a healthcare option, which is important as the world navigates the future of clinical research.
Elligo is the only organization that developed a continuum of technologies and data science capabilities. Its SOAR model increases patient access to reach various patient populations that typically don’t have access to clinical research as a care option. The solution brings efficiency by enabling direct data from source to submission and full remote site access, helping patients, physicians, and sponsors to conduct trials efficiently and faster in conventional and decentralized models.
Along with mitigating risk, SOAR adheres to regulations and improves data quality while decreasing resource requirements and costs associated with clinical research. Coupled with technology-enabled services and expert personnel, this latest model accelerates research without compromising on quality and integrity. This offers a pathway to either use conventional research sites or hybrid trials seamlessly moving between options without causing any problem for stakeholders. This shapes clinical research for a new paradigm in a new age of clinical research.
Elligo Health Research uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. The company’s expert team provides access to the best healthcare experts and research technologies. Its platforms engage physicians and patients who otherwise would not participate in clinical research and accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.